

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Wolfgang HEIL et al.

Serial No.: 09/654,227

Filed: August 31, 2000



Group: 1617

RECEIVED

DEC 27 2000

TECH CENTER 1600/2900

For: **PHARMACEUTICAL COMPOSITION FOR USE AS A CONTRACEPTIVE**

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:


This Information Disclosure Statement is being submitted in connection with Applicants' continuing duty of disclosure under 37 C.F.R. §1.56.

This statement is being filed before the mailing date of the first office action on the merits in accordance with 37 C.F.R. §1.97(b). Therefore, no fee is required herein.

Applicants wish to bring to the examiner's attention the references cited in the attached PTO-1449. EP 0253 607 corresponds to GB 2,192,542; WO 95/17194 corresponds to US 5,583,129 and WO 95/26730 corresponds to US 5,756,490. Copies of the references are provided herewith.

Applicants respectfully request the Examiner to confirm review of such documents by initialing and returning the attached PTO-1449.

Respectfully submitted,


Jennifer Branigan (Reg. No. 40,921)
Patent Agent

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza 1
2200 Clarendon Blvd., Suite 1400
Arlington, Virginia 22201
Telephone: (703) 812-5305
Internet Address: jbranigan@mwzb.com

Filed: 22 December 2000
JJB:K:PATPlovinn1 Alids NO sr.wpd